
-
AnaptyBio Inc NasdaqGS:ANAB AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Location: 10770 Wateridge Circle, San Diego, CA, 92121-5801, United States | Website: https://www.anaptysbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
659.1M
Cash
339.9M
Avg Qtr Burn
-27.2M
Short % of Float
50.03%
Insider Ownership
5.06%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JEMPERLI (Dostarlimab-gxly) Details Solid tumor/s, Cancer, Endometrial cancer | Approved Quarterly sales | |
Jemperli (dostarlimab) + Zejula (niraparib) Details Ovarian cancer, Cancer | Phase 3 Data readout | |
Dostarlimab+ belrestotug Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Dostarlimab Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Imsidolimab (ANB019) (anti-IL-36R) Details Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne | Phase 3 Update | |
Phase 2b Data readout | ||
Rosnilimab (ANB030) (PD-1 agonist) Details Ulcerative colitis | Phase 2 Data readout | |
ANB033 (anti-CD122 antagonist antibody) Details Inflammatory disease | Phase 1b Update | |
ANB101 (BDCA2 modulator) Details Ulcerative colitis | Phase 1 Initiation | |
ANB032 (BTLA agonist) Details Atopic dermatitis | Failed Discontinued | |
Rosnilimab (ANB030) (PD-1 agonist) Details Alopecia areata, Vitiligo, Skin disease/disorder | Failed Discontinued | |
Etokimab (ANB020) Anti-IL-33 Details Chronic Rhinosinusitis with Nasal Polyps | Failed Discontinued |